Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention

Medical Clinics of North America

Volumn 86, Issue 3, 2002, Pages 477-499

  Román, Gustavo C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CINNARIZINE; CITICOLINE; CYCLANDELATE; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GALANTAMINE; ISOXSUPRINE; MEMANTINE; NAFTIDROFURYL; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NICARDIPINE; NICERGOLINE; NICOTINIC ACID; NIMODIPINE; OXIRACETAM; PAPAVERINE; PENTOXIFYLLINE; PIRACETAM; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VASODILATOR AGENT;

ALZHEIMER DISEASE; BINSWANGER ENCEPHALOPATHY; BRAIN INFARCTION; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; HEART ARRHYTHMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LEUKOENCEPHALOPATHY; MULTIINFARCT DEMENTIA; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; STROKE;

AGED; ALZHEIMER DISEASE; CEREBROVASCULAR ACCIDENT; DEMENTIA, VASCULAR; HUMANS; INCIDENCE; NEUROPROTECTIVE AGENTS; RISK FACTORS;

EID: 0036327146     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00008-1     Document Type: Review

References (155)

1. Vascular dementia
2. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group
3. Stroke, disability, and dementia. Results of a population survey
4. A historical review of the concept of vascular dementia: Lessons from the past for the future
5. On the history of lacunes, état criblé, and the white matter lesions of vascular dementia
6. Observations on the brains of demented old people
7. Multi-infarct dementia: A cause of mental deterioration in the elderly
8. Pathology and pathophysiology of cerebrovascular dementia: Pure subgroups of obstructive and hypoperfusive etiology
9. Frontal systems impairment following multiple lacunar infarcts
10. Why do frontal lobe symptoms predominate in vascular dementia with lacunes?
11. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
12. Frontal-subcortical circuits and human behavior
13. Frontal-subcortical circuits and neuropsychiatric disorders
14. Anatomic and behavioral aspects of frontal-subcortical circuits
15. Frontal-subcortical circuits: The anatomic basis of executive, social and motivated behaviors
16. Executive frontal functions
17. Prefrontal neurons in networks of executive memory
18. Frontal-subcortical circuits: The anatomic basis of executive, social and motivated behaviors
19. Vascular subcortical dementias: Clinical aspects
20. Subcortical dementia as a manifestation of cerebrovascular disease
21. Senile dementia of the Binswanger type: A vascular form of dementia in the elderly
22. Executive control function: A rational basis for the diagnosis of vascular dementia
23. Features of cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficits: An anatomical study
24. Vascular changes in the human senile brain
25. Cortical blood vessels of the human brain
26. Medullary arteries in aging and dementia
27. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly: II. Postmortem pathological correlations
28. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly: A morphometric correlation with arteriolosclerosis
29. Decreased cerebral blood flow precedes multiinfarct dementia, but follows senile dementia of the Alzheimer type
30. Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type
31. Low blood pressure and dementia in elderly people: The Kungsholmen Project
32. Hypotension and cognitive impairment: Selective association in patients with heart failure
33. Cognitive impairment in congestive heart failure? Embolism vs hypoperfusion
34. Evidence for cortical "disconnection" as a mechanism of age-related cognitive decline
35. Thalamocortical diaschisis: Positron emission tomography in humans
36. Executive function and magnetic resonance imaging subcortical hyperintensities in vascular dementia
37. The cerebellar cognitive affective syndrome
38. Vascular dementia
39. Vascular dementia, a new beginning. Shifting focus from clinical phenotype to ischemic brain injury
40. The prevalence of dementia: A quantitative integration of the literature
41. Clinico-neuropathological correlations in Alzheimer's disease and related dementia
42. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series
43. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study
44. Pre-existing dementia in stroke patients: Baseline frequency, associated factors and outcome
45. Post-stroke dementia: Incidence and relationship to pre-stroke cognitive decline
46. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings
47. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study
48. The incidence of dementia. A meta-analysis
49. The incidence of vascular dementia in Canada: A comparison with Europe and East Asia
50. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort
51. After stroke: Frequency, patterns, and relationship to functional abilities
52. Dementia as a predictor of adverse outcomes following stroke. An evaluation of diagnostic methods
53. Clinical determinants of dementia related to stroke
54. How can cerebral infarcts and hemorrhages lead to dementia?
55. Vascular dementia: The role of cerebral infarcts
56. A quantitative MRI study of vascular dementia
57. Cranial computed tomographic observations in multi-infarct dementia: A controlled study
58. Risk factors for incident dementia after stroke. Role of hypoxic ischemic disorders
59. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer's disease
60. From UBOs to Binswanger's disease. Impact of MRI on VaD research
61. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study
62. Vascular dementia today
63. Unilateral amnesic stroke: Six new cases and a review of the literature
64. Amnesia after anterior communicating artery aneurysm rupture
65. Angular gyrus syndrome simulating Alzheimer's disease
66. Démence thalamique d'origine vasculaire par ramollissement bilatéral, limité au territoire du péduncule retromamillaire. A propos de deux observations anatomo-cliniques
67. Thalamic infarcts
68. Caudate infarcts
69. Confusion and memory loss from capsular genu infarction: A thalamocortical disconnection syndrome?
70. Strategic infarcts in vascular dementia. A clinical and imaging experience
71. Extensive metabolic and neuropsychological abnormalities associated with discrete infarction of the genu of the internal capsule
72. Subcortical dementia associated with striking enlargement of the Virchow-Robin spaces and transneural degeneration of the left mammillo-thalamic tract
73. Research criteria for subcortical vascular dementia in clinical trials
74. Des foyers lacunaires de désintégration et de différents autres états cavitaires du cerveau
75. Leukoaraiosis: An ancient term for a new problem
76. Die abgrenzung der allgemeinen progressiven paralyse (referat, erstattet auf der jahres versammlung des vereins deutscher irrenärtzte zu dresden am 20 Sept, 1894
77. The identity of lacunar dementia and Binswanger disease
78. Pure subcortical arteriosclerotic encephalopathy (Binswanger's disease): A clinicopathological study. Part I: Clinical features
79. Pure subcortical arteriosclerotic encephalopathy (Binswanger's disease): A clinicopathological study. Part II: Pathologic features
80. Binswanger's disease - Revisited
81. Lacunar dementia
82. Autosomal dominant syndrome with stroke-like episodes and leukoencephalopathy
83. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12
84. Summary of the Proceedings of the First International Workshop on CADASIL. Paris, May 19-21, 1993
85. Encéphalopathie sous-corticale progressive (Binswanger) àévolution rapide chez deux soeurs
86. CADASIL in a North American family. Clinical, pathologic, and radiologic findings
87. The phenotypic spectrum of CADASIL: Clinical findings in 102 cases
88. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: A positron emission tomography study in two affected family members
89. Systemic vascular smooth muscle impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
90. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis
91. Strong clustering and stereotyped nature of mutations in CADASIL patients
92. Familial British dementia with amyloid angiopathy: Early clinical, neuropsychological and imaging findings
93. Systemic amyloid deposits in familial British dementia
94. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
95. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
96. Clock drawing is sensitive to executive control: A comparison of six methods
97. Reliabilities, norms and factor structure of the Behavioral Dyscontrol Scale
98. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease
99. Neuropathologic substrates of ischemic vascular dementia
100. Meta-analysis of the Hachinski ischemic score in pathologically verified dementias
101. Current concepts in mild cognitive impairment
102. Untangling vascular dementia
103. Status of risk factors for vascular dementia
104. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study
105. Predictors of cognitive change in the Cardiovascular Health Study: The role of cardiovascular and genetic risk factors
106. Effect of antihypertensive treatment in patients having already suffered from stroke: Gathering the evidence
107. Stroke, statins and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
108. Antiplatelet agents for secondary prevention of ischemic stroke
109. Prevention of stroke in patients with nonvalvular atrial fibrillation
110. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis
111. 15-Year longitudinal study of blood pressure and dementia
112. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
113. Hypertension and dementia
114. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension
115. Statins and the risk of dementia
116. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
117. Statins and neuroprotection
118. Cholesterol and Alzheimer's disease: Is there a link?
119. Congestive heart failure and cognitive impairment in an older population
120. New insight into Binswanger disease
121. Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
122. Therapeutic strategies for vascular dementia
123. Concluding remarks
124. Perspectives in the treatment of vascular dementia
125. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-infarct Dementia Trial
126. An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia
127. Piracetam for dementia or cognitive impairment. (Cochrane Review)
128. Oxiracetam in dementia: A double-blind, placebocontrolled study
129. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia
130. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis
131. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia
132. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
133. CDP-choline: Pharmacological and clinical review
134. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia
135. Memantine in severe dementia: Results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine)
136. New approaches to clinical trials in vascular dementia: Memantine in small vessel disease
137. Clinical review: Pentoxifylline
138. Pentoxifylline study. Study EPM-ID
139. Pentoxifylline in cerebrovascular dementia
140. Hemorheological changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer's type: Adverse effects on cerebromicrovascular system
141. Aspirin for vascular dementia
142. Triflusal in the prevention of vascular dementia
143. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease
144. Is vascular dementia really Alzheimer's disease or mixed dementia?
145. Alzheimer's disease and vascular dementia. Some points of confluence
146. Overlap between pathology of Alzheimer disease and vascular dementia
147. Anterior choroidal artery infarction presenting as a progressive cognitive deficit
148. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia
149. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
150. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types
151. Results of clinical studies with donepezil in vascular dementia
152. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
153. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up
154. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomized trial